Premium Information is available for this item - Upgrade for $1 a day
6505-01-135-3174
Theophylline Extended-Release Tablets
6505011353174 011353174 CONSTANT-T NDC00028-0042-73
January 2023
4
Marketplace 6505-01-135-3174
Request a Quotation from participating marketplace vendors
Related Documents 6505-01-135-3174 5+ Documents (More...)
RQST NE Updated Every Day 6505-01-135-3174 RQST Updated Every Day 6505-01-135-3174 RQST NE Related Documents
6505-01-135-3174 5+ Documents ( More... ) https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-135-3174
Tablets your Account Upgrade 6505-01-135-3174Theophylline Extended-Release Tablets6505011353174 011353174
CONSTANT-T https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-201-0809 Theophylline Extended-Release
/fsc-6505/us 6505-01-201-0809 Extended-Release Tablets www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-135-3174
6505/us 6505-01-201-0809 fsg-65/fsc-6505/us 6505-01-268-7538 Theophylline Extended-Release Tablets 011353174
Theophylline Extended-Release Tablets Extended-Release Tablets6505011353174 011353174 https//www.nsnlookup.com
/fsc-6505/us 6505-01-083-6613 www.nsnlookup.com https//www.nsnlookup.com /fsg-65/fsc-6505/us 6505-01-135-3174
Theophylline Extended-Release Tablets Extended-Release Tablets 011353174 https//www.nsnlookup.com
215-4389 6505-01-094-1613 6505-01-093-9476 6505-43-000-6418 6505-01-201-0809 6505-01-268-7538 6505-01-135-3174
Restrictions 6505-01-135-3174
6505-01-135-3174 is a Theophylline Extended-Release Tablets that does not have a nuclear hardened feature or any other critical feature such as tolerance, fit restriction or application. Demilitarization of this item has been confirmed and is not currently subject to changes. This item is considered a low risk when released from the control of the Department of Defense. The item may still be subject to the requirements of the Export Administration Regulations (EAR) and the Code of Federal Regulations (CFR). This item may be hazardous as it is in a Federal Supply Class for potentially hazardous items. A MSDS should be available from the supplier for the end user to evaluate any hazards. This item does not contain a precious metal.
Import and Export 6505-01-135-3174
- Schedule B
- Subscribe to View Schedule B
- HTS Code
- Subscribe to View HTS Code
End Users 6505-01-135-3174
- MOE Rule:
- V542
- Effective Date:
- 1 Apr 1991
Approved Sources 6505-01-135-3174
- Part Number
- Manufacturer
- Status
- NDC00028-0042-73
- Manufacturer
- 97423 - Ciba-Geigy Corp (Active)
- Primary Buy
- Primary Buy
- CONSTANT-T
- 97423 - Ciba-Geigy Corp (Active)
- Incomplete Secondary Reference
- Incomplete Secondary Reference
Datasheet 6505-01-135-3174
- Characteristic
- Specifications
- FIIG
- Specifications
- A510N0
- Active Medicament Medicinal Strength [AKJA]
- 200.000 Milligrams Theophylline, Anhydrous Active Ingredient
- Primary Container Type [CQCT]
- Bottle
- Primary Container Content Quantity [CRLK]
- 60.000 Tablets
- Special Features [FEAT]
- Child Resistant Closure And 3 Part Label;Long Action Method:Extended Release;
Management Data 6505-01-135-3174
- Effective Date
- Organization
- Unit of Issue
- Unit Price
- Qty Unit Pack
- Unit of Issue
- Sep 1991
- Veterans Administration (VA)
- BT
- Subscribe
- BT
- MOE
- USC
- Code
- Statement
- Order of Use
- Jump To Code
- Qty Per Assy
- UOM
- Technical Document
- Quantative Expression
- Code
- Veterans Administration (VA)
- V
- K
- U/I Contains 60 Tt
- 00000000060TT
- K
NATO Stock Numbers Related to 6505-01-135-3174
Freight Information 6505-01-135-3174
6505-01-135-3174 has freight characteristics.. 6505-01-135-3174 has a variance between NMFC and UFC when transported by rail and the description should be consulted.